Patents by Inventor Apoorva MULAY

Apoorva MULAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230174946
    Abstract: Described herein are particular infection model systems, methods of studying infection, and method of screening compounds in various model systems. Particularly, SARS-CoV-2 is studied in these organ and infection models.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Applicants: CEDARS-SINAI MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Barry R. Stripp, Apoorva Mulay, Bindu Konda, Arun Sharma, Clive Svendsen, Vaithilingaraja Arumugaswami, Dhruv Sareen, Hanan Shaharuddin, Victoria Wang, Roberta S. Santos
  • Publication number: 20230167413
    Abstract: The in vitro organoid model is a major technological breakthrough and an essential tool to study the basic biology of an organ system and for the development of various clinical applications for disease intervention. Organoids can self-renew and exhibit similarities in function as of their tissue of origin. Here, a step-by-step protocol is described to isolate region-specific progenitors from the human lung and generate 3D organoid cultures as an experimental and validation tool.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 1, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Barry R. Stripp, Bindu Konda, Apoorva Mulay
  • Publication number: 20210147811
    Abstract: Described herein are methods and compositions for regulation of the p53 pathway, providing intrinsic “sternness” allowing for their efficient in vitro expansion following isolation. Pharmacologic approaches to modulate p53 signaling supports expansion of stem cells, including greater clonal expansion of lung stem cells when compared to use of other small molecules such as ROCK inhibitor Y27632 alone. Effects of combined treatment with Pifithrin-? and Y27632 are additive. The current invention involves use of drugs that target the p53 pathway to reversibly regulate stem cell expansion in vitro for banking of stem cells and for pre-conditioning of stem cells prior to orthotopic transplantation.
    Type: Application
    Filed: April 9, 2019
    Publication date: May 20, 2021
    Applicant: Cedars-Sinai Medical Center
    Inventors: Barry STRIPP, Apoorva MULAY, Changfu YAO